Physician profile
Sanjay Kumar
NPI 1205948288
$9,408.70
in general payments reported to CMS, 2019-2025
31 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $1,489 · 2021: $2,511 · 2022: $1,033 · 2023: $219 · 2024: $303 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,495.69 | 2019-2025 | Avvigo Guidance System, Watchman Access System, Rotapro |
| Astrazeneca Pharmaceuticals Lp | $958.28 | 2019-2025 | Wainua, Farxiga |
| Amgen INC. | $908.06 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $751.30 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $647.21 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $611.86 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $442.08 | 2019-2022 | |
| Pfizer INC. | $417.55 | 2019-2025 | |
| Amarin Pharma, INC. | $365.30 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $354.03 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.38 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $288.83 | 2020-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $281.31 | 2019-2025 | Amvuttra, Onpattro |
| Philips North America LLC | $238.69 | 2021 | |
| Abbott Laboratories | $191.78 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $167.65 | 2019-2022 | |
| Medtronic Vascular, INC. | $152.66 | 2019-2020 | |
| Irhythm Technologies, INC. | $147.38 | 2022-2023 | Zio Xt Patch |
| Abbvie INC. | $116.06 | 2021 | |
| Bridgebio Pharma, INC. | $112.09 | 2025 | Attruby |
| Medtronic, INC. | $78.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.30 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $53.51 | 2019 | |
| Bardy Diagnostics, INC. | $53.51 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $39.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.19 | 2025 | |
| Tactile Systems Technology INC | $32.58 | 2020 | |
| Portola Pharmaceuticals, LLC | $28.73 | 2019 | |
| Glaxosmithkline, LLC. | $28.18 | 2021 | |
| W. L. Gore & Associates, INC. | $18.61 | 2019 | |
| Cardiovascular Systems INC. | $4.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.